Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06633913 · ClinicalTrials.gov registry record · NA
Concurrent TMS-fMRI
A NA study of Depression and Healthy Control, sponsored by Jing Jiang.
- Recruiting
- Registry status
- NA
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT06633913: Recruiting NA study of Depression and Healthy Control, sponsored by Jing Jiang.
NCT06633913 is a NA study of Depression and Healthy Control that is actively recruiting participants, run by Jing Jiang. The registered enrollment target is 97 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06633913, a NA study of Depression and Healthy Control, is actively recruiting participants, sponsored by Jing Jiang.
- RECRUITING
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to examine the neural mechanisms underlying transcranial magnetic stimulation (TMS) using concurrent functional magnetic resonance imaging (fMRI) in both healthy controls (HCs) and patients with high negative affect symptoms, such as depression. Approximately half male and half female participants aged 18-65 will be recruited. The main questions it aims to answer are: 1. Is the acute/transient effect induced by single-pulse TMS related to the long-term modulatory effect induced by repetitive TMS (rTMS)? 2. Do any of these effects predict negative affect symptoms, such as depression? Participants will: 1. Complete several tests to assess their cognitive abilities and emotional states 2. Undergo several brain scans, including resting-state fMRI, structural MRI, diffusion tensor imaging (DTI), and task fMRI 3. Have two different types of TMS sequences, single-pulse and repetitive pulses, administered to specific brain regions while undergoing fMRI
Primary Outcome
The primary outcome measure will be the modulation effect of TBS to the dlPFC, which is the difference between TMS-induced acute/transient effects before and after TBS. The acute/transient effects will be assessed through single-pulse TMS-induced fMRI blood oxygenation level-dependent (BOLD) responses. The difference in BOLD response before and after TBS (i.e., TBS modulation effect) will be assessed using paired t-tests reported with t and p values.
Conditions Studied
Interventions
- DEVICE spTMS-TBS-spTMS
Study Locations (1)
Iowa
- University of Iowa Carver College of Medicine - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2024-04-19 |
| Est. Completion | 2029-01-31 |
| Phase | NA |
What NCT06633913 shows while recruiting
NCT06633913 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which spTMS-TBS-spTMS is the first listed.
NCT06633913 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT06633913 about?
NCT06633913 is a clinical study titled "Concurrent TMS-fMRI". The goal of this clinical trial is to examine the neural mechanisms underlying transcranial magnetic stimulation (TMS) using concurrent functional magnetic resonance imaging (fMRI) in both healthy controls (HCs) and patients with high negative affect symptoms, such as depression. Approximately half ...
What is the current status of trial NCT06633913?
This trial is currently recruiting. It is a NA study. The enrollment target is 97 participants. The study started on 2024-04-19. Estimated completion is 2029-01-31.
What conditions does trial NCT06633913 study?
This clinical trial studies the following conditions: Depression, Healthy Control.
What interventions are being tested in trial NCT06633913?
The interventions under investigation include: spTMS-TBS-spTMS (DEVICE).
Who is sponsoring clinical trial NCT06633913?
This trial is sponsored by Jing Jiang, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06633913 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06633913's enrollment target sits among peer trials
97 351st of 679 higher than 328 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy